key: cord-0698668-87gi3wpi authors: Voss, C.; Esmail, S.; Liu, X.; Knauer, M.; Ackloo, S.; Kaneko, T.; Lowes, L.; Stogios, P.; Seitova, A.; Hutchinson, A.; Yusifov, F.; Skarina, T.; Evdokimova, E.; Loppnau, P.; Ghiabi, P.; Haijian, T.; Zhong, S.; Abdoh, H.; Hedley, B.; Bhayana, V.; Martin, C.; Slessarev, M.; Chin-Yee, B.; Fraser, D.; Chin-Yee, I.; Li, S. title: Epitope-resolved serology test differentiates the clinical outcome of COVID-19 and identifies defects in antibody response in SARS-CoV-2 variants date: 2021-03-20 journal: nan DOI: 10.1101/2021.03.16.21253716 sha: e3544c606f4addd8dea7f8a86cbc684d08b520d8 doc_id: 698668 cord_uid: 87gi3wpi BACKGROUND. The role of humoral immunity in the coronavirus disease 2019 (COVID-19) is not fully understood owing, in large part, to the complexity of antibodies produced in response to the SARS-CoV-2 infection. There is a pressing need for serology tests to assess patient-specific antibody response and predict clinical outcome. METHODS. Using SARS-CoV-2 proteome and peptide microarrays, we screened 146 COVID-19 patients plasma samples to identify antigens and epitopes. This enabled us to develop a master epitope array and an epitope-specific agglutination assay to gauge antibody responses systematically and with high resolution. RESULTS. We identified 54 linear epitopes from the Spike (S) and Nucleocapsid (N) protein and showed that epitopes enabled higher resolution antibody profiling than protein antigens. Specifically, we found that antibody responses to the S(811-825), S(881-895) and N(156-170) epitopes negatively or positively correlated with clinical severity or patient survival. Moreover, we found that the P681H and S235F mutations associated with the coronavirus variant B.1.1.7 altered the specificity of the corresponding epitopes. CONCLUSIONS. Epitope-resolved antibody testing not only offers a high-resolution alternative to conventional immunoassays to delineate the complex humoral immunity to SARS-CoV-2 and differentiate between neutralizing and non-neutralizing antibodies, it may also be used as predictor of clinical outcome. The epitope peptides can be readily modified to detect antibodies against variants in both the peptide array and latex agglutination formats. FUNDING. Ontario Research Fund (ORF)-COVID-19 Rapid Research Fund, the Toronto COVID-19 Action Fund, Western University, the Lawson Health Research Institute, the London Health Sciences Foundation, and the AMOSO Innovation Fund. LFA-based tests have been shown less sensitive and specific than ELISA (6, 9, 11, 12) . Besides concerns over sensitivity, specificity and POC potential, both ELISA-and LFA-based antibody testing have the following limitations. First, current tests rely on the interaction of the Spike (S) or Nucleocapsid (N) protein or a fragment/domain of either protein to capture the corresponding antibody. These assays, which provide a single measure of antibody reactivity, are not ideal for gauging the diverse antibody responses observed in the clinic. Second, protein antigen-based immunoassays such as ELISA and LFA generate a composite signal across many epitopes, including both conformational and linear epitopes, and thereby lacking the necessary specificity or resolution to differentiate between neutralizing and nonneutralizing antibodies or predict clinical outcome. Indeed, patients who are older or with severe symptoms have been shown to produce more antibodies than those who are younger or with milder symptoms (13, 14) , suggesting that robust antibody responses measured by conventional means do not correlate with effective humoral immunity. Third, current serological assays are ill-suited to assess the immunological effect of coronavirus variants as numerous recombinant proteins would have to be produced. Several mutated strains have emerged recently that are believed to be more contagious than the original SARS-CoV-2 strain (15, 16) . These and other variants identified to date harbor numerous missense or deletion mutations in the S or N protein encoding gene that may alter their antigenic characteristics. To effectively curb the spread of these highly contagious variants, it is of paramount importance that we develop an antibody test that can readily incorporate the emerging mutations to determine the effect of these mutations and the corresponding coronavirus variants on the immune system. Fourth, current immunoassays are generally focused on testing a specific antibody isotype. Given the distinct dynamics of IgM, IgA and IgG in response to the SARS-CoV-2 infection (17, 18) , it is necessary to develop a multiplex immunoassay to gauge humoral immunity. Lastly, with the vaccine rollout across the globe, a rapid and accurate POC test is urgently needed to gauge the effectiveness of a vaccine and monitor the duration of antibody responses in large populations to provide valuable information on herd immunity. We addressed these unmet needs in SARS-CoV-2 antibody testing using protein and peptide arrays, which led to the identification of linear epitopes that mediate the complex antibody responses observed in a group of 89 COVID-19 patients. This, in turn, allowed us to develop a "master epitope array" containing the major epitopes and use it to gauge antibody responses with greater resolution than is attainable by protein antigen-based immunoassays. We found that the antibody profiles determined by linear epitopes, but not by the S or N protein, could distinguish patients with moderate or severe diseases Antibody specificity is determined by epitopes on the protein antigen, including both linear and conformational epitopes (23) . Because linear epitopes are small peptides (5-20 residues), they may be identified by screening peptides generated by chemical or genetic means (19, 20, 22) . To identify the linear epitopes mediating the SARS-CoV-2 antibody responses, we synthesized peptides representing the candidate epitopes reported in the literature (up to October 2020)(24, 25) and printed the peptides on a nitrocellulose coated glass slide. The resulting peptide array, containing 89 reported epitopes for the S, N, and M (membrane) proteins ( Fig. 2A) , was probed with patient plasma samples. Intriguingly, we were only able to detect <50% of the reported epitopes in our peptide array screens ( Fig. S3 ; Table S2 ). While the large discrepancy might be attributed, in part, to the different techniques used for assaying the epitope-antibody interaction, it prompted us to redefine the epitopes using the peptide array approach. To this end, we created a peptide microarray to represent the complete S and N protein sequences. The resulting "peptide-walking" array contained 333 tiled 15-mer peptides with 5-residue overlap between two consecutive peptides ( Fig. 2A) . 7 We screened the peptide microarray with 15 patient plasma samples, including 14 COVID-19 patient samples and 1 SARS-CoV-2control (Fig. S4 ). This led to the identification of 54 potential epitopes from the S and N protein (Table 1) . While the majority of the candidate epitopes are likely minor ones based on the weak IgG-binding signals, some produced strong signals (Fig. S4 , Table 1 ), suggesting that they may be major epitopes mediating the S or N antibody response. To profile antibody response in a systematic manner, we generated a "master epitope array" containing 16 major epitopes selected based on the corresponding IgG signal strength from the peptide-walking array screen. The master array also contained S and N protein antigens as controls ( Fig. 2A ; Table 1 ; Fig. S5 ). Using the master array, we screened plasma samples from the 89 COVID-19 patients and 9 SARS-CoV-2control subjects ( Fig. 2 B-C; Fig. S6 ). We found that the plasma from ICU (severe) group recognized significantly more epitopes than the non-ICU (moderate) group (Fig. 3A) . Certain epitopes, including S-811, S-881, N-6 and N-361, were detected more frequently in the severe cases than in the moderate cases whereas other epitopes, including S-451 and N-156, showed the opposite trend (Fig. 3B ). By comparison, the number of IgG-binding epitopes were not significantly different between patients who survived or succumbed to the disease even though the latter group, in general, tended to have antibodies reactive to more epitopes (Fig. 3C) . Nevertheless, antibodies to the S-811, S-881 and N-361 epitopes were found enriched in the fatality group whereas antibodies to N-6, S-451, S-551 and S-671 were detected only in the survivor group (Fig. 2D ). In addition to epitope frequency, the intensity of IgG-binding signals to certain epitopes were found correlated positively or negatively with clinical severity or outcome. In general, we found that moderate cases tended to have stronger antibody responses to N-156 whereas more robust antibody responses against the S-811 and S-881 epitopes were observed for the severe cases (Fig. 3E) . Indeed, COV+14 was the only moderate case among the tested cases with strong S-811 and S-881 antibodies which, intriguingly also featured a robust S-671 antibody response. Overall, the patients with fatal disease were characterized with significantly stronger S-811-or S-881-specific antibodies than those who survived the infection (Fig. 3F ). This indicates that antibody responses to these epitopes are detrimental to COVID-19 disease progression. The S-811 and S-881 epitopes are located in a region of the spike protein buried in the prefusion conformation, which, however, becomes disordered and exposed following virus 8 fusion with the host cell membrane (Fig. 3G) . Therefore, it is likely that the production of antibodies specific for the S-811-or S-881 epitopes coincides with the state of the coronavirus undergoing active host cell infection. In contrast, the S-671 epitope, mutated in the UK variant B.1.1.7, is located at the S1/S2 cleavage site critical for virus infection(26) (Fig. 3G ). Numerous mutations have been identified in SARS-CoV-2 variants, the vast majority of which occur on the spike protein which plays a critical role in host cell infection and immune response. The recent emergence of several variants in the United Kingdom (UK), South African (SA) and Brazil, which have been shown to be more contagious than the original strain, has raised concerns over the efficacy of mRNA vaccines that are used to produce the wild-type Spike protein in the recipient. We investigated this possibility using peptides representing 28 major S or N missense mutations or deletions identified to date, including those found in the UK variant B.1.1.7., the SA variant 501.V2 and mutations shown to alter antibody binding in a previous study(27) ( Table 2) . A peptide array containing the mutated epitopes and the matching counterparts in the original SARS-CoV-2 strain was created and screened with patient plasma (Fig. 4A ). Because only a few mutations reside within the identified epitopes (Table 2) , the mutated epitope screen was focused on plasma samples that showed robust antibody responses to the corresponding wild-type epitopes on the master array (Fig. 2B) . Intriguingly, we found that the mutations either reduced or completely abolished IgG binding for the corresponding epitopes. A rapid agglutination assay to gauge epitope-specific antibody response While the epitope peptide array may be used to determine antibody specificity in a systematic manner, it is not suitable for POC testing. Nevertheless, the identification of specific epitopes that are either common to the COVID-19 patients examined or unique to groups with distinct clinical severity or outcome prompted us to develop a rapid test based on these epitopes to complement the peptide array assay. Inspired by the principle of antibody-dependent red blood cell agglutination(28), we developed an epitope-dependent agglutination assay to detect epitope-specific antibody response. Specifically, latex beads were coated with streptavidin and conjugated to one or more biotinylated epitope peptides. Antibodies specific to the epitopes were found to induce the agglutination of the corresponding latex beads in minutes (Fig. 5A) , with the area of agglutination serving as a proxy of antibody titer. In principle, the latex bead agglutination assay detects the total antibodies (including IgG, IgM and IgA) rather than a specific isotype. To develop an epitope test to replace the S and N antigens, we coated the latex beads with the most prominent S or N epitopes. Specifically, latex beads were coated with a mixture of the S-811 and S-1146 (2S) peptides to represent the S antigen or the N-156 and N-361 (2N) peptides to represent the N antigen. When evaluated using plasma samples from individuals who tested positive (COVID+) or negative (COVID-) for the SARS-CoV-2 virus or samples from healthy donors collected in 2018 (PreCOVID), the 2S-and 2N-based agglutination assays showed 100% specificity and 99%-100% sensitivity (Fig. 5B ). To determine if the epitope-dependent agglutination assay could differentiate the different patient groups as effectively as the master epitope array, we coated the latex beads with the S epitope S-811, S-881 or S-551 or the N epitope N-156 or N-361 and performed agglutination assay on COVID-19 patient plasma or control (COVID-) specimen. While no agglutination was observed for the COVID-plasma, the COVID+ plasma promoted the agglutination of the latex beads in an epitope-dependent manner. We found that the group with severe disease had significantly greater S-811-and N-361-specific antibody responses than the group with moderate conditions. The reverse was found true for the N-156 epitope. Similarly, significant differences in antibodies specific for the S-811, S-881, S-551 and N-156 epitopes were observed between the alive and fatality groups. Notably, a high level of S-811-dependent 10 agglutination was strongly and significantly correlated with patient death whereas even a moderate level of S-551-specific antibody response was correlated significantly with favorable outcome. These data not only reinforced our findings from the master epitope peptide array screen but extended these findings by identifying a group of key epitopes, including S-811, S-881, S-551 and N156, that collectively may help predict the clinical severity and outcome of the COVID-19 disease. Because neutralizing antibodies play a pivotal role in the humoral immune response to the SARS-CoV-2 infection, we used a surrogate neutralization assay to measure efficacy of patient plasma in blocking S-RBD binding to its host receptor, angiotensin converting enzyme 2 (ACE2) in vitro(29). We found that the neutralization efficiency of the plasma in the severe patient group was significantly higher than the group with moderate disease. Intriguingly, the plasma from the fatality group were significantly less efficient in neutralizing S-RBD binding to ACE2 compared to patients who recovered from the infection ( Fig. 6A ). This suggests that the ability to inhibit the S-RBD-ACE2 interaction, the critical first step in SARS-CoV-2 infection of host cells, dictates disease outcome. Because the identified S epitopes reside outside of the RBD domain of the spike protein, due perhaps to the possibility that the antibody-RBD recognition involves primarily conformational epitopes(23), we replaced the S epitopes with recombinant RBD and repeated the agglutination assay using the same plasma samples. We found that the S-RBD-dependent antibody response measured by latex agglutination significantly correlated with favorable outcome (Fig. 6B ). Can the epitope-specific antibody response be used to predict neutralization efficiency? We investigated this possibility by correlating the epitope-specific agglutination data with the neutralization data for the same set of patient samples. We found that the S-811-specific antibody response correlated with the neutralization efficiency negatively (r=-0.72, p<0.05) in the alive patient group, but positively in the severe (r=0.68) or fatality (r=0.64) patient group. In contrast, the S-RBD-dependent agglutination efficiency was positively correlated with neutralization efficiency (r=0.68) in the alive group(30) (Fig. 6C ). Collectively, these data suggests that a strong S-RBD antibody response together with a weak S-811-specific response are indicative of favorable clinical outcome. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 20, 2021. The relationship between COVID-19 clinical severity and the humoral immune response is a complex one. It remains poorly understood to date why patients with severe symptoms are characterized with a stronger antibody response, including neutralization antibodies, to SARS-CoV-2 than those who have moderate or mild symptoms (30, 31) . This dichotomy suggests that not all antibodies are beneficial. Indeed, while antibodies may mediate the clearance of the virus and virus-infected cells through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), they have also been proposed to play a pathogenic role via antibody-dependent enhancement (ADE) (32) . The challenge is how to identify and differentiate between "good" and "bad" antibodies. Our epitope-based antibody analysis showed that the antibody responses from different patients are highly varied, and that there is generally no apparent association between the severity of disease presentation and antibody response measured using a protein antigen, including the Spike (N) or Nucleocapsid (N). Therefore, antibody profiling with greater resolution than a simplified S or N antibody classification is needed. Our work, which combines both systematic antibody screen using peptide/protein arrays and rapid antibody assays based on latex agglutination, showed that epitope-resolved antibody testing is far more sensitive than S/N-based serology tests in discerning antibody specificity and identifying the correlates between humoral immunity and COVID-19 disease severity or patient survival. By identifying and validating the major S and N epitopes to enable epitope-specific antibody testing, our study not only greatly extended previous work that show linear epitopes play a critical role in mediating antibody responses to SARS-CoV-2 (19, 20, 22, 24, 33) , but more importantly, it demonstrated that the complex antibody responses in individual patients may be deconvoluted by epitope-resolved antibody profiling. Systematic and unbiased antibody profiling using a master array comprising the most prominent epitopes led to several intriguing findings. First, patients with severe disease or poor outcome tend to have antibodies against a large number of epitopes. We showed that these same patients had low levels of neutralizing antibodies. It is therefore likely that the increased production of non-neutralizing antibodies contributed to disease development. Second, all epitopes are not equal, and even the epitopes from the same protein antigen (S or N) may play distinct roles in dictating disease severity and outcome. We have shown that not only S-811 and S-881 are two of the most prevalent epitopes, but also a high level of antibodies specific for these epitopes are strongly indicative of severe or fatal disease. That the S-811 antibody response is negatively correlated with neutralization efficiency in patients who survived the infection suggests that the S-811-driven antibody response may be indicative of more aggressive or 12 effective virus infection of the host cells. Alternatively, antibody response targeting these epitopes may be a surrogate marker for a more robust and potentially excessive immune response causing greater tissue injury. Third, we have shown that mutations found in SARS-CoV-2 variants may directly affect antibody response by altering epitope specificity. This finding demonstrated the flexibility of the epitope peptide array approach to quickly incorporate emerging mutations, thereby providing valuable information of the mutations and the corresponding variants on the immune system. While it has been shown that mutations result in more fit, and likely more contagious viruses (15, 16, 34) , the serological consequences of the mutations found in SARS-CoV-2 variants are unclear (34) . Recent studies have shown reduced binding to therapeutic antibodies or Spike-specific antibodies for the circulating variants B.1.1.7, 501Y.V2 and P.1 in vitro (35, 36) , suggesting that mutations in these variants directly affect antibody response. In agreement with this assertion, we found that certain mutations, including the P681H in the Spike and S245F in the Nucleocapsid proteins, rendered the corresponding epitopes completely incapable of binding antibodies specific for the original virus. This observation raises concerns over the effectiveness of vaccines in protecting against the coronavirus variants that are currently circulating or variants, including variant recombination, that may emerge in the future (14). While it remains to be determined whether this mutation could mediate immune escape of the variant in some patients, our finding may have far-reaching implications as it may render the wildtype Spike mRNA-based vaccine less effective to those who employ S-671 (which encompass the mutated residue) as a major epitope. However, we note that the P681H and S235F mutations only affected a few individuals in the cohort of patients examined herein while the majority of patients displayed no apparent antibody responses against the corresponding epitopes. This may explain why recent studies have shown the Pfizer and Moderna mRNA vaccines are effective in protecting from infection by the variant (37-39). It would be important to investigate in the future, by large-scale epitopespecific antibody profiling, the percentage of the population who employ S-671 as a major epitope. By the same token, prevalence of the N-221 epitope (which contains the S235 residue found mutated in the UK strain) would provide valuable information on the protection of vaccines based on inactivated intact viruses. In the same vein, hundreds of mutations may be examined simultaneously in a peptide array to assess their effect on antibody response, and the epitope array may be readily modified to incorporate emerging mutations. The impact of the mutations on humoral immune response may also involve conformational epitopes which are not recapitulated by the linear epitopes. However, both the master array and the agglutination-based antibody test may be quickly modified to include emerging mutations. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 20, 2021. ; 13 Future studies using a combination of epitope and protein antigen-based assays tailored to emerging variants would provide valuable information on the population penetrance of a given variant and the impact the associated missense or deletion mutations on antibody-mediated immunity. While the epitope array may be used to profile antibody response in a systematic manner, the epitopedependent latex agglutination assay provides a rapid, simple, cost-effective, and accurate serological test that may be suitable for POC antibody testing. The agglutination assay may be carried out with individual epitopes to map the specificity of antibodies or with a mixture of epitopes to test multiple antigens simultaneously. The ease with which to incorporate mutated epitopes or S/N protein antigen in the agglutination assay makes it a nimble yet powerful tool to determine the impact of mutations associated with the coronavirus variants on humoral immunity. Although the mRNA-based vaccines have shown superb efficacy, not all vaccine recipients would be protected. It also remains to be determined how long the immunity will last and against which variant. Monitoring vaccinated or recovered individuals over months to years by antibody testing would provide valuable information on the duration of immune responses against SARS-CoV-2, including variants (7) . In this regard, the epitope-resolved antibody test may be used to delineate the specific antibodies produced by different individuals, determine persistence of antibody in the circulation over time, assess the efficiency of vaccines, and decipher the effect of emerging variants on the immune system. The agglutination assay, which measures the total antibody response irrespective of the Ig isotypes, provides a unique advantage over serological assays that measure a given isotype as different Ig isotypes have distinct dynamics and evolutionary trajectory over time (18) . Longitudinal studies by the epitope-resolved agglutination assay would provide valuable information on the evolution of antibody immunity from vaccination or previous infection. With the rapid spread of the highly contagious coronavirus variants, the number of patients that need treatment will likely remain high for quite some time. In the absence of an effective treatment, convalescent plasma and antibody therapy remain a good option. However, clinical trial results are mixed for either approach, highlighting the need for more specific screening strategies to identify the most effective convalescent plasma or therapeutic antibody. It would be interesting to find out if the epitoperesolved antibody profiling strategy developed herein may be used to identify convalescent plasma donors with a high level of neutralization antibody and a low level of non-neutralizing and potentially harmful antibodies. Similarly, the epitope specificity mapping could enable the selection of the most effective therapeutic antibody with the least side-effects. CoV-2 Spike and Nucleocapsid proteins were synthesized for array printing. Peptides reported in a previous publication(24) as well as epitopes predicted using bioinformatics(25) were synthesized and printed to create the literature-reported peptide array. Peptides encompassing mutation sites reported in SARS-CoV-2 variants were synthesized as described above for the variant peptide array ( Table 2) . (1:250 dilution in ChonBlock). Slides were then rinsed quickly three times followed by three 5min washes with TBST before probing with goat anti-human IgG HRP antibody at 1:10,000 (Millipore Sigma) in ChonBlock for 1h. The wash step was repeated as above, then the HRP signal was visualized on a ChemiDoc XRS+ Imager (Bio-Rad) using Clarity ECL Substrate (Bio-Rad). Slides were incubated with ECL solution for 30 seconds then 15 images were taken incrementally from 1-60 seconds. All incubation steps were performed at room temperature using a rocker for agitation of sample. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 20, 2021. ; Peptide walking arrays, literature-reported epitope peptide arrays and the master epitope arrays were quantified using ImageJ software(42). Images were first inverted and converted to 8-bit. Background was subtracted using a rolling ball radius of 25.0 pixels. Intensities were normalized to IgG control and ranked by normalized signal intensity. Peptides with strongest intensity or most frequently observed were selected for creation of the master array. For the master array, samples with no detectable antibody response or samples with signals within 2 standard deviations of the mean background intensity were omitted from statistical analysis. Blue dyed carboxylate-modified, streptavidin-polystyrene latex beads, 0.25 µm in diameter or blue dyed polystyrene latex beads, 0.8 ϻm in diameter, were purchased from Sigma Aldrich (L6155, L1398). Carboxylate-modified latex-streptavidin or neutravidin coated polystyrene beads were suspended at 2.5% (w/v) using assay buffer, 0.025M MES-Tween 20 buffer (2-(N-Morpholino) ethanesulfonic acid, 0.05% pH 6.0). Synthetic biotin-labeled SARS-CoV-2 peptides were suspended in the same assay buffer at the concentration 500µg/ml. The biotin-peptides were incubated with streptavidin-latex beads for 1 hour at room temperature. The epitope peptide-conjugated latex beads complex was washed twice with PBS buffer (135 mM NaCl, 2.6 mM KCl, 8 mM Na2HPO4, and 1.5 mM KH2PO4, pH 7.4) by mixing and centrifuging the latex suspension at 5,000g for 10 min. The peptide antigen-bead conjugate was blocked for 30 min at room temperature in PBS containing 3% bovine serum albumin (BSA). The conjugate was then resuspended at 2.5% (w/v) in PBS containing 1% BSA and stored at 4°C until use. For the agglutination assay, 5 µl plasma was mixed with 25 µl peptide-conjugated latex beads (2.5%, w/v) per assay as described in the full protein antigen agglutination assay. For the agglutination assay, 5 μl plasma was mixed with 25 µl antigen-coated beads (2.5%, w/v) per assay. The agglutination was allowed to proceed for 2 min at room temperature before imaging with a camera. The relative degree of agglutination induced by the SARS-CoV-2 antibody was measured by the area of clump formation based on the corresponding image. The image analysis software Qupath (v0.1.2) was used (https://qupath.github.io/) and quantification was done by calculating the percentage of agglutination based on estimated agglutination/clumps area (mm 2 ) relative to the total latex reaction area. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The S protein has two cleavage sites, S1/S2 and S2'. The S-671 epitope is located at the C-terminus of S1, and it is disordered in the prefusion cryo-EM structure (left panel: PDB 6XR8). A homology model from the SWISS-MODEL repository was employed to draw an S-671 epitope model in the left panel (colored blue), without cleavage at S1/S2. The Pro681 site is shown with a red sphere. The S2' cleavage site is located on the S-811 epitope. The S-881 epitope is buried and inaccessible in the prefusion state. However, the region (fusion peptide or FP) targets the host cell membrane and is fully All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 20, 2021. ; 23 disordered in the post-fusion conformation (right panel: PDB 6XRA, residues 771-911 are disordered). The S1 region is colored orange, except for RBD in cyan. The region between S1/S2 cleavage and S2' cleavage sites is in green. The S-811 and S-881 epitopes are colored magenta in the prefusion conformation. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 20, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. G All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. S-881 are shown on the domain structure diagram of Spike as well as its prefusion (left) and postfusion (right) conformation. The S protein has two cleavage sites, S1/S2 and S2'. The S-671 epitope is located at the C-terminus of S1, and it is disordered in the prefusion cryo-EM structure (left panel: PDB 6XR8). A homology model from the SWISS-MODEL repository was employed to draw an S-671 epitope model in the left panel (colored blue), without cleavage at S1/S2. The Pro681 site is shown with a red sphere. The S2' cleavage site is located on the S-811 epitope. The S-881 epitope is buried and inaccessible in the prefusion state. However, the region (fusion peptide or FP) targets the host cell membrane and is fully disordered in the post-fusion conformation (right panel: PDB 6XRA, residues 771-911 are disordered). The S1 region is colored orange, except for RBD in cyan. The region between S1/S2 cleavage and S2' cleavage sites is in green. The S-811 and S-881 epitopes are colored magenta in the prefusion conformation. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 20, 2021. ; IgG N165Q N165 N234Q N234 V367F V367 Q414E Q414 N439K N439 L452R L452 I468F I468T I468 IgG A475V A475 V483A V483 F490L F490 Y508H Y508 A522V A522 D614G D614 N709Q N709 PBS IgG A831V A831 PBS PBS K417N K417 E484K E484 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Natural History of Asymptomatic SARS-CoV-2 Infection Asymptomatic SARS-CoV-2 infection: the tip or the iceberg? Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis Test performance evaluation of SARS-CoV-2 serological assays. medRxiv A serological assay to detect SARS-CoV-2 seroconversion in humans SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population Serology testing in the COVID-19 pandemic response. The Lancet Infectious Diseases UK and other SARS-CoV-2-Covariants -Simulation Modeling 70% Increase The basis of a more contagious 501Y.V1 variant of SARS-COV-2. bioRxiv Cov-2 IgM and IgG antibodies among COVID-19 patients Evolution of antibody immunity to SARS-CoV-2 Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity Epitopes for a 2019-nCoV vaccine Epitoperesolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates A perspective on potential antibody-dependent enhancement of SARS-CoV-2 SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibodymediated immunity